These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 18247475)

  • 21. Hypoxia downregulates farnesoid X receptor via a hypoxia-inducible factor-independent but p38 mitogen-activated protein kinase-dependent pathway.
    Fujino T; Murakami K; Ozawa I; Minegishi Y; Kashimura R; Akita T; Saitou S; Atsumi T; Sato T; Ando K; Hara S; Kikugawa K; Hayakawa M
    FEBS J; 2009 Mar; 276(5):1319-32. PubMed ID: 19187229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How epithelial cells detect danger: aiding the immune response.
    Vroling AB; Fokkens WJ; van Drunen CM
    Allergy; 2008 Sep; 63(9):1110-23. PubMed ID: 18699929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dietary procyanidins lower triglyceride levels signaling through the nuclear receptor small heterodimer partner.
    Del Bas JM; Ricketts ML; Baiges I; Quesada H; Ardevol A; Salvadó MJ; Pujadas G; Blay M; Arola L; Bladé C; Moore DD; Fernandez-Larrea J
    Mol Nutr Food Res; 2008 Oct; 52(10):1172-81. PubMed ID: 18720348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Noninvasive imaging of receptor function: signal transduction pathways and physiological readouts.
    Rudin M
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):606-15. PubMed ID: 18729012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Single-Cell Perspective of the Mammalian Liver in Health and Disease.
    Xiong X; Kuang H; Liu T; Lin JD
    Hepatology; 2020 Apr; 71(4):1467-1473. PubMed ID: 31997380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Proteome and its application in liver diseases research].
    Geng CX; Wang JY
    Zhonghua Gan Zang Bing Za Zhi; 2002 Aug; 10(4):314-5. PubMed ID: 12223156
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacology and therapeutics of constitutively active receptors. Preface.
    Tao YX
    Adv Pharmacol; 2014; 70():ix-x. PubMed ID: 24931204
    [No Abstract]   [Full Text] [Related]  

  • 28. No smokescreen.
    New Sci; 2003 Oct 4-10; 180(2415):3. PubMed ID: 14686418
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of autophagy in liver diseases: mechanisms and potential therapeutic targets.
    Cursio R; Colosetti P; Codogno P; Cuervo AM; Shen HM
    Biomed Res Int; 2015; 2015():480508. PubMed ID: 25866785
    [No Abstract]   [Full Text] [Related]  

  • 30. Celebrating 15 Years: A Toast to Health, Longevity, and Metabolism.
    Mott R; Fabbiano S; Levinson R; Evans A
    Cell Metab; 2020 Jan; 31(1):1-2. PubMed ID: 31914375
    [No Abstract]   [Full Text] [Related]  

  • 31. Molecular endocrinology: A portal for enhanced access and utility of the nuclear receptor signaling atlas (NURSA) web resource.
    McKenna NJ; DeFranco DB
    Mol Endocrinol; 2009 Jun; 23(6):739. PubMed ID: 19470797
    [No Abstract]   [Full Text] [Related]  

  • 32. Cutaneous receptors: clinical implications and therapeutic relevance. Preface.
    Wolf R; Davidovici BB
    Dermatol Clin; 2007 Oct; 25(4):xiii-xiv. PubMed ID: 17903605
    [No Abstract]   [Full Text] [Related]  

  • 33. Focus.
    Friedman SL
    J Hepatol; 2011 May; 54(5):841-3. PubMed ID: 21232564
    [No Abstract]   [Full Text] [Related]  

  • 34. Resminostat: Opening the door to epigenetic treatments for liver cancer.
    Zhao J; Lawless MW
    Hepatology; 2016 Feb; 63(2):668-9. PubMed ID: 25891162
    [No Abstract]   [Full Text] [Related]  

  • 35. [Therapeutic assessment, 1956-1961. Hepatology].
    TRAISSAC FJ; BERAUD C
    Gaz Med Fr; 1956-1961; (Special)():423-39. PubMed ID: 14037883
    [No Abstract]   [Full Text] [Related]  

  • 36. [Experiences with the therapeutic effects of peat fulvic acid].
    BERES T; KIRALY I; BONA E; LOVEI E; SZILARD R
    Wien Z Inn Med; 1958 Apr; 39(4):170-1. PubMed ID: 13570154
    [No Abstract]   [Full Text] [Related]  

  • 37. Preface: a special issue on nuclear receptors with a special view on the molecular basis of disease.
    Moschetta A
    Biochim Biophys Acta; 2011 Aug; 1812(8):807. PubMed ID: 21664556
    [No Abstract]   [Full Text] [Related]  

  • 38. Adis therapeutic value rating.
    Drugs R D; 2003; 4(3):160. PubMed ID: 12825554
    [No Abstract]   [Full Text] [Related]  

  • 39. Nuclear receptors as therapeutic targets in cholestatic liver diseases.
    Zollner G; Trauner M
    Br J Pharmacol; 2009 Jan; 156(1):7-27. PubMed ID: 19133988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver-enriched nuclear receptors: therapeutic opportunities.
    Staudinger JL
    Mol Pharm; 2008; 5(1):1-2. PubMed ID: 18247475
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.